The Role of KRAS rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical Testing

Annika Lindblom, James M. Flanagan, Hoda Anton-Culver, Ellen L. Goode, Wendy Brewster, Matthias Dürst, Georgia Chenevix-Trench, James P. LaPolla, Diana M. Eccles, Kathryn L. Terry, Christine Walsh, Lotte Nedergaard (+101 others)
An assay for the single nucleotide polymorphism (SNP) rs61764370 has recently been commercially marketed as a clinical test to aid ovarian cancer risk evaluation in women with family histories of the disease. rs67164370 is in a 3′UTR miRNA binding site of the KRAS oncogene, and is a candidate for epithelial ovarian cancer (EOC) susceptibility. However, only one published paper, analyzing fewer than 1,000 subjects in total, has examined this association.
doi:10.17615/kvd4-4s97 fatcat:zwkdfjmdkrhrhehhrijaybnrra